Mesoblast (MESO) Net Income towards Common Stockholders Growth (3y) (2018 - 2025)

Mesoblast (MESO) Net Income towards Common Stockholders Growth (3y) (2018 - 2025) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Income Growth (3y) (Qtr)
1 Alterity Therapeutics 925,601.88 Bn 925,601.85 Bn - -
2 Belite Bio 58,560.00 Bn 58,560.00 Bn - 84.25%
3 Quantum Biopharma 17,284.41 Bn 17,284.40 Bn - -10.84%
4 Legend Biotech 2,809.00 Bn 2,808.71 Bn 242.10 Mn 26.38%
5 Evaxion A 1,334.43 Bn 1,334.42 Bn - 34.98%
6 Akari Therapeutics 1,312.27 Bn 1,312.26 Bn - -46.86%
7 Psyence Biomedical 212.16 Bn 212.16 Bn - -
8 Vertex Pharmaceuticals 114.83 Bn 107.58 Bn 2.59 Bn 13.80%
9 Abivax 91.96 Bn 91.96 Bn - -
10 Mesoblast 21.68 Bn 21.55 Bn - -53.83%

Historic Data

Download Data
DateValue
Dec 31, 2025 -53.83%
Jun 30, 2025 11.81%
Dec 31, 2024 -56.70%
Jun 30, 2024 24.88%
Dec 31, 2023 -48.38%
Jun 30, 2023 3.00%
Mar 31, 2023 -80.99%
Dec 31, 2022 -0.13%
Sep 30, 2022 -45.48%
Jun 30, 2022 -0.39%
Mar 31, 2022 -5.16%
Dec 31, 2021 1.78%
Sep 30, 2021 -5.11%
Jun 30, 2021 -54.44%
Mar 31, 2021 56.52%
Dec 31, 2020 40.59%
Sep 30, 2020 -51.76%
Jun 30, 2020 -18.59%
Dec 31, 2019 43.17%
Sep 30, 2019 34.81%